| Preop Centers Of Tennessee, Llc | |
|
9245 Poplar Ave # 5-210 Germantown TN 38138-7931 | |
| (210) 469-3830 | |
| Not Available |
| Full Name | Preop Centers Of Tennessee, Llc |
|---|---|
| Speciality | General Practice |
| Location | 9245 Poplar Ave # 5-210, Germantown, Tennessee |
| Authorized Official Name and Position | Adam Bruggeman (MANAGING MEMBER) |
| Authorized Official Contact | 2103733704 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Preop Centers Of Tennessee, Llc 9245 Poplar Ave # 5-210 Germantown TN 38138-7931 Ph: () - | Preop Centers Of Tennessee, Llc 9245 Poplar Ave # 5-210 Germantown TN 38138-7931 Ph: (210) 469-3830 |
| NPI Number | 1487385241 |
|---|---|
| Provider Enumeration Date | 06/22/2022 |
| Last Update Date | 06/22/2022 |
| Certification Date | 06/22/2022 |
| Medicare PECOS PAC ID | 5799150983 |
|---|---|
| Medicare Enrollment ID | O20230330002075 |
News Archive
Nektar Therapeutics announced today that positive data from the first single-ascending dose Phase 1a clinical study of NKTR-192, the company's novel short-acting mu-opioid analgesic candidate, demonstrate that the drug candidate achieved its target pharmacokinetic profile.
Nektar Therapeutics announced today that data presented at the European Society for Medical Oncology (ESMO) 12th World Congress on Gastrointestinal Cancer demonstrates that NKTR-102, the company's lead oncology compound, exhibits superior activity compared to irinotecan as part of either a monotherapy or combination regimen in tumor models of gastrointestinal cancers.
A team of researchers at the Salk Institute has found two therapeutic targets for the deadly type of lung cancer, non-small-cell lung carcinomas (NSCLCs), which accounts for 85 percent of all lung cancer cases. They believe that the breakthrough discovery could pave the way for the development of new treatments for a majority of lung cancer patients.
Most infectious diseases infect multiple host species, but to date, efforts to quantify the frequency and outcome of cross-species transmission (CST) of these diseases have been severely limited.This lack of information represents a major gap in knowledge of how diseases emerge, and from which species they will emerge.A paper published this week in the journal Science by a team of researchers led by Daniel Streicker of the University of Georgia has begun to close that gap.
› Verified 9 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1487385241 | NPI | - | NPPES |
| Provider Name | Adam Bruggeman |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1316160625 PECOS PAC ID: 8729240973 Enrollment ID: I20230330002272 |
News Archive
Nektar Therapeutics announced today that positive data from the first single-ascending dose Phase 1a clinical study of NKTR-192, the company's novel short-acting mu-opioid analgesic candidate, demonstrate that the drug candidate achieved its target pharmacokinetic profile.
Nektar Therapeutics announced today that data presented at the European Society for Medical Oncology (ESMO) 12th World Congress on Gastrointestinal Cancer demonstrates that NKTR-102, the company's lead oncology compound, exhibits superior activity compared to irinotecan as part of either a monotherapy or combination regimen in tumor models of gastrointestinal cancers.
A team of researchers at the Salk Institute has found two therapeutic targets for the deadly type of lung cancer, non-small-cell lung carcinomas (NSCLCs), which accounts for 85 percent of all lung cancer cases. They believe that the breakthrough discovery could pave the way for the development of new treatments for a majority of lung cancer patients.
Most infectious diseases infect multiple host species, but to date, efforts to quantify the frequency and outcome of cross-species transmission (CST) of these diseases have been severely limited.This lack of information represents a major gap in knowledge of how diseases emerge, and from which species they will emerge.A paper published this week in the journal Science by a team of researchers led by Daniel Streicker of the University of Georgia has begun to close that gap.
› Verified 9 days ago
| Provider Name | John Bryan Clifton |
|---|---|
| Provider Type | Practitioner - Anesthesiology |
| Provider Identifiers | NPI Number: 1336117381 PECOS PAC ID: 3577581503 Enrollment ID: I20230330002426 |
News Archive
Nektar Therapeutics announced today that positive data from the first single-ascending dose Phase 1a clinical study of NKTR-192, the company's novel short-acting mu-opioid analgesic candidate, demonstrate that the drug candidate achieved its target pharmacokinetic profile.
Nektar Therapeutics announced today that data presented at the European Society for Medical Oncology (ESMO) 12th World Congress on Gastrointestinal Cancer demonstrates that NKTR-102, the company's lead oncology compound, exhibits superior activity compared to irinotecan as part of either a monotherapy or combination regimen in tumor models of gastrointestinal cancers.
A team of researchers at the Salk Institute has found two therapeutic targets for the deadly type of lung cancer, non-small-cell lung carcinomas (NSCLCs), which accounts for 85 percent of all lung cancer cases. They believe that the breakthrough discovery could pave the way for the development of new treatments for a majority of lung cancer patients.
Most infectious diseases infect multiple host species, but to date, efforts to quantify the frequency and outcome of cross-species transmission (CST) of these diseases have been severely limited.This lack of information represents a major gap in knowledge of how diseases emerge, and from which species they will emerge.A paper published this week in the journal Science by a team of researchers led by Daniel Streicker of the University of Georgia has begun to close that gap.
› Verified 9 days ago
News Archive
Nektar Therapeutics announced today that positive data from the first single-ascending dose Phase 1a clinical study of NKTR-192, the company's novel short-acting mu-opioid analgesic candidate, demonstrate that the drug candidate achieved its target pharmacokinetic profile.
Nektar Therapeutics announced today that data presented at the European Society for Medical Oncology (ESMO) 12th World Congress on Gastrointestinal Cancer demonstrates that NKTR-102, the company's lead oncology compound, exhibits superior activity compared to irinotecan as part of either a monotherapy or combination regimen in tumor models of gastrointestinal cancers.
A team of researchers at the Salk Institute has found two therapeutic targets for the deadly type of lung cancer, non-small-cell lung carcinomas (NSCLCs), which accounts for 85 percent of all lung cancer cases. They believe that the breakthrough discovery could pave the way for the development of new treatments for a majority of lung cancer patients.
Most infectious diseases infect multiple host species, but to date, efforts to quantify the frequency and outcome of cross-species transmission (CST) of these diseases have been severely limited.This lack of information represents a major gap in knowledge of how diseases emerge, and from which species they will emerge.A paper published this week in the journal Science by a team of researchers led by Daniel Streicker of the University of Georgia has begun to close that gap.
› Verified 9 days ago
Aba Memphis Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 1687 Cordova Rd, Germantown, TN 38138 Phone: 901-461-7222 | |
Wholeheart Women's Christian Counseling Inc. Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 8570 Cordes Cir Ste 10, Germantown, TN 38139 Phone: 901-483-3660 Fax: 901-221-8380 | |
Customized Medical Needs Mental Health Clinic Medicare: Medicare Enrolled Practice Location: 2129 West Street, Suite 224, Germantown, TN 38138 Phone: 866-563-7772 Fax: 901-255-0758 | |
Firefly Therapy Services, Pllc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 2171 Judicial Dr Ste 111, Germantown, TN 38138 Phone: 901-305-9565 | |
Optum Behavioral Care Of North Carolina, Pc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 2262 S Germantown Rd, Germantown, TN 38138 Phone: 901-153-4300 | |
Germantown Private Psychiatry Pllc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 7505 Capital Dr, The Corporate Center, Germantown, TN 38138 Phone: 901-730-0575 Fax: 901-730-0389 | |
The Medical Psychology Group Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 7655 Poplar Ave, Suite 365, Germantown, TN 38138 Phone: 901-751-3571 Fax: 901-751-3572 |